Any current/future capex/capital investment/strategic investment?

Expansion of IIL Biologicals R&D Center planned on a 7-acre shared site, including establishing a new plant and strengthening R&D activities. Continuous strengthening of manufacturing capabilities to support new technology and product development. Focus on all-round development including marketing, sales, and R&D to support growth and premium product launches. Strategic investment in Kaeros acquisition to enable import of raw technical materials, expand B2B segment, and launch a second brand, unlocking new distributor networks. Ongoing development and launch of multiple new products, including

Future growth expectations in sales/revenue/volumes?

Company expects growth in both domestic and international markets, especially from biological products, with ongoing small launches in this segment. Around half a dozen new product launches are lined up in the next 12-18 months, including 4 slated for the current month. Growth in premium (Maharatna) products is a key focus, with about 10% volume growth already seen; generics are being rationalized. Export order book is strong with over INR100 crores in orders, signaling good export market recovery. B2C segment expected to grow; B2B and international business showing initial signs of im

Future growth expectations in earnings/operating earnings/profits/EPS?

Management expects good performance in H2 FY'25, indicating overall growth in earnings and operating profits. Continuous focus on new premium (Maharatna) product launches, with 4 new launches planned soon, expected to drive sales and profitability. EBITDA margins of around 14.3% in Q2 and 12.5% in H1 suggest margins may sustain or improve with growth. Recovery expected from sales returns impact faced in Q2, with efforts on rationalizing product mix towards premium products likely to support margin expansion. Export order book is strong, with over INR100 crores in orders, supporting revenue and

Current/ Expected Orderbook/ Pending Orders?

The export order book is full, with orders already collected to match last year's export sales of approximately INR 105 crores. Additional export orders amounting to over INR 100 crores are already in hand. The company is managing capacity by dedicating an additional unit beyond the SEZ unit to meet these export demands. The B2B segment does not have a large order book; orders received are routine but indicate recovery. The overall export order book is strong and continues to accept new orders.

Insecticid.IndiaQ2 FY25Fertilizers & Agrochemicals

Insecticid.India Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹569P/E: 14.0Market Cap: ₹1.8K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Company expects growth in both domestic and international markets, especially from biological products, with ongoing small launches in this segment.
Around half a dozen new product launches are lined up in the next 12-18 months, including 4 slated for the current month.
Growth in premium (Maharatna) products is a key focus, with about 10% volume growth already seen; generics are being rationalized.
Export order book is strong with over INR100 crores in orders, signaling good export market recovery.
B2C segment expected to grow; B2B and international business showing initial signs of improvement.
Despite some sales return due to weather-related challenges, company aims to compensate with new product introductions in the second half.
Outlook for full-year FY25 growth may see some moderation but company targets growth in both top line and bottom line.
Improved operational efficiencies and strengthening of brand "Tractor" expected to drive growth.

Margin guidance

Category 3

Management expects good performance in H2 FY'25, indicating overall growth in earnings and operating profits.
Continuous focus on new premium (Maharatna) product launches, with 4 new launches planned soon, expected to drive sales and profitability.
EBITDA margins of around 14.3% in Q2 and 12.5% in H1 suggest margins may sustain or improve with growth.
Recovery expected from sales returns impact faced in Q2, with efforts on rationalizing product mix towards premium products likely to support margin expansion.
Export order book is strong, with over INR100 crores in orders, supporting revenue and profit growth.
Biologicals segment is anticipated to grow independently, contributing positively in the medium term.
Company targets sustainable top-line growth; though 15% growth in FY'25 may be challenging, moderate growth is expected.
Overall, management is optimistic about earnings and EPS growth, backed by product innovation, market expansion, and operational efficiencies.

See what Insecticid.India management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or future fundraising plans through debt or equity for Insecticides India Limited. Key points related to financial strategy noted are: - Focus on disciplined financial management and value creation. - Improvement in working capital days from 151 days in March 2024 to 102 days in September 2024. - Emphasis on strengthening R&D, manufacturing, marketing, and product launches without explicit mention of raising funds. - No references to planned equity issuance or debt raising during the call or transcript. Therefore, based on the available information, there is no indication of any new fundraising through debt or equity at present or in the immediate future.

Order book

Yes

The export order book is full, with orders already collected to match last year's export sales of approximately INR 105 crores.
Additional export orders amounting to over INR 100 crores are already in hand.
The company is managing capacity by dedicating an additional unit beyond the SEZ unit to meet these export demands.
The B2B segment does not have a large order book; orders received are routine but indicate recovery.
The overall export order book is strong and continues to accept new orders.

See what Insecticid.India management said on order book — free account, 30 seconds.

Capex plans

Yes

Expansion of IIL Biologicals R&D Center planned on a 7-acre shared site, including establishing a new plant and strengthening R&D activities.
Continuous strengthening of manufacturing capabilities to support new technology and product development.
Focus on all-round development including marketing, sales, and R&D to support growth and premium product launches.
Strategic investment in Kaeros acquisition to enable import of raw technical materials, expand B2B segment, and launch a second brand, unlocking new distributor networks.
Ongoing development and launch of multiple new products, including biologicals and patented compounds, to increase market presence and profitability.
Investment in team building and technology adoption (CRM, training modules) to strengthen sales and technical support teams.

Track Insecticid.India — get its next earnings analysis in your feed

How does Insecticid.India rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisInsecticid.India

Rev 4Mar 3

See where Insecticid.India sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Insecticid.India rank in Fertilizers & Agrochemicals?

Compare Insecticid.India against every Fertilizers & Agrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Insecticid.India's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Advance Agrolife Ltd (Q4 FY26)
Q4 FY26 total revenue: ₹1,259.07 million, up 40% YoY (Page 24). Key concall takeaways from Advance Agrolife Ltd's Q4 FY26 earnings call — and how it ranks…
Advance Agrolife Ltd (Q1 FY27)
Q1 FY27 revenue from operations: ₹3,304 million, a 96% year-on-year (YoY) increase (Page 23, 25, 22). Key concall takeaways from Advance Agrolife Ltd's Q1 FY27…
Bhagiradha Chemicals & Industries Ltd (Q4 FY26)
158.1 crores . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Bhagiradha Chemicals & Industries Ltd (Q1 FY27)
195.0 crore . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →